Today TherapeuticsMD Inc (TXMD) Stock Crashes

August 11, 2017 - By Vivian Currie

Investors sentiment increased to 1.54 in 2016 Q4. Its up 0.22, from 1.32 in 2016Q3. It increased, as 15 investors sold TherapeuticsMD Inc shares while 35 reduced holdings. 31 funds opened positions while 46 raised stakes. 162.01 million shares or 5.89% more from 152.99 million shares in 2016Q3 were reported.
Parametric Port Associates Limited Liability Corporation has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 64,641 shares. Credit Suisse Ag owns 128,097 shares for 0% of their portfolio. State Bank Of America De has invested 0% in TherapeuticsMD Inc (NYSEMKT:TXMD). Morgan Stanley has 515,309 shares. Metropolitan Life Insur Com New York has invested 0% in TherapeuticsMD Inc (NYSEMKT:TXMD). Clearline Cap L P has invested 0.12% in TherapeuticsMD Inc (NYSEMKT:TXMD). 232,340 are held by Alliancebernstein Limited Partnership. Legal And General Grp Public Limited has invested 0% in TherapeuticsMD Inc (NYSEMKT:TXMD). Great Point Ltd Company reported 3.28 million shares. Jpmorgan Chase invested 0.02% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Point72 Asset Mgmt L P accumulated 203,300 shares. Grp One Trading Lp holds 65,664 shares or 0% of its portfolio. Menta Capital Limited Liability holds 0.03% or 68,785 shares. Moreover, State Bank Of Montreal Can has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 74,719 shares. Blackrock Grp Inc Limited stated it has 122,441 shares.

The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) is a huge mover today! About 2.35 million shares traded. TherapeuticsMD Inc (NYSEMKT:TXMD) has declined 46.30% since August 11, 2016 and is downtrending. It has underperformed by 63.00% the S&P500.
The move comes after 5 months negative chart setup for the $1.14B company. It was reported on Aug, 11 by Barchart.com. We have $5.37 PT which if reached, will make NYSEMKT:TXMD worth $45.60M less.

TherapeuticsMD Inc (NYSEMKT:TXMD) Ratings Coverage

Among 4 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TherapeuticsMD had 6 analyst reports since September 21, 2015 according to SRatingsIntel. The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) earned “Buy” rating by Jefferies on Tuesday, November 22. On Tuesday, December 8 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating by Jefferies given on Monday, September 21. Stifel Nicolaus maintained it with “Buy” rating and $14.0 target in Tuesday, December 8 report. The stock of TherapeuticsMD Inc (NYSEMKT:TXMD) has “Outperform” rating given on Tuesday, November 22 by Oppenheimer.

More recent TherapeuticsMD Inc (NYSEMKT:TXMD) news were published by: Fool.com which released: “Why TherapeuticsMD Inc Is Getting Clobbered” on July 17, 2017. Also Businesswire.com published the news titled: “TherapeuticsMD Announces Second Quarter 2017 Financial Results” on August 03, 2017. Benzinga.com‘s news article titled: “Mid-Day Market Update: Sevcon Surges Following Acquisition News …” with publication date: July 17, 2017 was also an interesting one.

TherapeuticsMD, Inc. is a women’s healthcare firm engaged in creating and commercializing products for women. The company has market cap of $1.14 billion. The Firm is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. It currently has negative earnings. The Company’s drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.